Skip to Content
Director, Holden Comprehensive Cancer CenterProfessor of Internal Medicine
- Hematology, Oncology and Blood and Marrow Transplantation
Primary Office: 5970-Z JPPIowa City, IA 52242
Email: firstname.lastname@example.orgWeb: Weiner Translational Research LaboratoryWeb: Holden Comprehensive Cancer CenterWeb: Video remarksWeb: The Expertise within Holden Comprehensive Cancer Center (Video)Web: Big Ten Cancer Research Consortium (Video)Web: The University of Iowa Holden Comprehensive Cancer Center (Video)Web: Health at Iowa - Cancer DNA therapies (Video)Web: Holden Comprehensive Cancer Center - University of Iowa Hospitals and Clinics (Video)
BA, Johns Hopkins UniversityMD, The Ohio State University
Residency, Internal Medicine, Medical College of OhioFellowship, Hematology and Oncology, University of Michigan
Subspecialty Board in Hematology, ABIMSubspecialty Board in Medical Oncology, ABIMAmerican Board of Internal MedicineNational Board of Medical Examiners
Interdisciplinary Graduate Program in ImmunologyInterdisciplinary Graduate Program in InformaticsInterdisciplinary Graduate Program in Translational BiomedicineMedical Scientist Training Program
Dr. Weiner’s research focuses on understanding the mechanisms of action of anti-cancer monoclonal antibodies, and on development of novel approaches to immunotherapy of lymphoma. He has been continually funded by the NCI since 1991 and has been the PI on the University of Iowa / Mayo Clinic Lymphoma Specialized Program of Research Excellence (P50 CA097274) since it was initiated in 2002. This grant was renewed competitively in 2007 and 2012. Dr. Weiner’s research extends from basic laboratory investigation to clinical trials. He was the first to demonstrate Toll Like Receptor 9 agonists could be used successfully as immune adjuvants in tumor immunization. He has made major contributions to our understanding of the mechanisms of action responsible for the anti-tumor activity of monoclonal antibodies, including providing evidence that, in some cases, complement can inhibit the efficacy of some monoclonal antibodies. He has established a number of collaborative research programs, including working with Dr. Aliasger Salem from the UI College of Pharmacy on novel uses of nanoparticles to enhance the anti-tumor immune response.
Date Last Modified: 06/06/2016 -
Copyright © 2015 The University of Iowa. All Rights Reserved.